News

SBIR grant interpretation hinders research

BIOTECHNOLOGY companies around the nation are working to develop new therapies for diseases such as cancer, Alzheimer’s and Parkinson’s, to name just a few.

Federal government officials at the Small Business Administration (SBA) in Washington are standing in the way of this medical innovation.

In 2003, the SBA changed its interpretation of eligibility requirements for Small Business Innovation Research (SBIR) grants.

Under the new interpretation, companies that are 51 percent owned by a group of venture- capital firms are no longer eligible for SBIR grants. Since this new interpretation prevents most innovative biotech companies from receiving crucial start-up money, this has potentially devastating effects on the future of the industry.

By James C. Greenwood

Full Story: http://www.pasadenastarnews.com/Stories/0,1413,206~11851~2989867,00.html

Posted in:

Sorry, we couldn't find any posts. Please try a different search.

Leave a Comment

You must be logged in to post a comment.